BSBenjamin Sahn

Benjamin Sahn

*This is an algorithmically generated author record based on publicly available information.

Benjamin Sahn has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Kristine Pascuma

    IMEC Garden City Eindhoven NY NLD USA

    3 shared publications
  • Petar Mamula

    Endoscopy Division of Gastroenterology, Hepatology & Nutrition Children's Hospital of Philadelphia (CHOP) Philadelphia Pennsylvania

    3 shared publications
  • Nina Kohn

    Feinstein Institutes for Medical Research, Manhasset, USA

    2 shared publications
  • Abhay Srinivasan

    Department of Radiology, Children's Hospital of Philadelphia, Philadelphia, PA; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

    1 shared publication
  • Andrew J. Klink

    The Children's Hospital of Philadelphia, Division of Pediatric Gastroenterology, Hepatology, & Nutrition, Philadelphia, PA, United States; Cardinal Health, Dallas, TX, United States

    1 shared publication
  • Anne Marie Mbbch Cahill

    Department of Radiology Division of Interventional Radiology Children's Hospital of Philadelphia (CHOP) Philadelphia Pennsylvania

    1 shared publication

Latest Publications

  • Open Access

    Abstracts from the Sixth Bioelectronic Medicine Summit: Neurotechnologies for Individuals and Communities

    by Nicolò Rossetti, Philipp Schnepel, Vojkan Mihajlović, Weiguo Song, Timir Datta-Chaudhuri, Stavros Zanos, Kristine Pascuma, Jillian Charyn, Kristen Lacey, Benjamin Sahn


  • Open Access

    Children With Inflammatory Bowel Diseases are Disadvantaged by Current Drug Approval Policies: A Call for Urgent Change

    by Benjamin Sahn, Ross M Maltz, Joel R Rosh

    Treatment of pediatric inflammatory bowel disease (IBD) is significantly hindered by the lack of US Food and Drug Administration-approved biologic and small-molecule medications. This review explains the burdens faced by children with IBD because of this problem and appraises the marked historical timeline differences in medication approval between adults and children with IBD. The authors follow with an in-depth focus on the pointed disparity in approved therapies for children with IBD compared to children with rheumatologic immune-mediated diseases, highlighting the differences in stringency of evidence that has been used to gain medication approval for children with rheumatologic diseases. The editorial concludes with a call for change in regulatory agency protocols, to adopt a modernized strategy that will expedite the approval of advanced therapies for children with IBD.


  • Open Access

    Transcutaneous auricular vagus nerve stimulation attenuates inflammatory bowel disease in children: a proof-of-concept clinical trial

    by Benjamin Sahn, Kristine Pascuma, Nina Kohn, Kevin J. Tracey, James F. Markowitz

    Background: Vagus nerve stimulation is an investigational anti-inflammatory therapy targeting the nervous system to modulate immune activity. This study evaluated the efficacy and safety of transcutaneous auricular VNS (ta-VNS) in patients with pediatric-onset Crohn’s disease (CD) or ulcerative colitis (UC). Methods: Participants were 10–21 years of age with mild/moderate CD or UC and fecal calprotectin (FC) > 200 ug/g within 4 weeks of study entry. Subjects were randomized to receive either ta-VNS targeting the cymba conchae of the external left ear, or sham stimulation, of 5 min duration once daily for a 2-week period, followed by a cross over to the alternative stimulation for an additional 2 weeks. At week 4, all subjects received ta-VNS of 5 min duration twice daily until week 16. Primary study endpoints were clinical remission, and a ≥ 50% reduction in FC level from baseline to week 16. Heart rate variability measurements and patient-reported outcome questionnaires were completed during interval and week 16 assessments. Results: Twenty-two subjects were enrolled and analyzed (10 CD, 12 UC). Six of 10 with CD had a wPCDAI > 12.5 and 6/12 with UC had a PUCAI > 10 at baseline, correlating to mild to moderate symptom activity. Among the 12 subjects with active symptomatic disease indices at baseline, clinical remission was achieved in 3/6 (50%) with CD and 2/6 (33%) with UC at week 16. Despite all subjects having FC levels ≥ 200 within 4 weeks of enrollment, five subjects (4 UC, 1 CD) had FC levels < 200 at the baseline visit and were excluded from the FC analysis. Of the remaining 17, median baseline FC was 907 µg/g (IQR 411–2,120). At week 16, 11/17 (64.7%) of those with baseline FC ≥ 200 had a ≥ 50% reduction in FC (95% CI 38.3—85.8). In the UC subjects, there was an 81% median reduction in FC vs baseline (833 µg/g; p = 0.03) while in the CD subjects, median reduction in FC at 16 weeks was 51% (357 µg/g; p = 0.09). There were no safety concerns. Conclusion: Noninvasive ta-VNS attenuated signs and symptoms in a pediatric cohort with mild to moderate inflammatory bowel disease. Trial Registration: NCT03863704—Date of registration 3/4/2019.


  • The Future of Advanced Therapies for Pediatric Crohn’s Disease

    by Julie Gallagher, Joel R. Rosh, Benjamin Sahn

    Pediatric Crohn’s disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respond over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule therapies, which have become available for adult patients since anti-tumor necrosis factor medications, is paramount for tighter disease control for a large proportion of children. Newer advanced therapies such as anti-integrin and anti-interleukin biologics, and several small-molecule agents capitalize on various mechanisms through narrower immunologic targets and reduced immunogenicity. Given limited regulatory approvals of these agents for use in children with Crohn’s disease, clinicians continue to rely on data extrapolated from clinical trials in adult patients, sparse pediatric studies, and a growing real-world experience for treatment selection and optimization. In this article, we discuss currently available treatment options, pipeline drugs, and relevant data as they pertain to some of the most pressing clinical challenges faced in treating pediatric Crohn’s disease.


  • Open Access

    Transcutaneous Auricular Vagus Nerve Stimulation Attenuates Inflammatory Bowel Disease in Children: A Proof-of-Concept Clinical Trial

    by Benjamin Sahn, Kristine Pascuma, Nina Kohn, Kevin J Tracey, James F Markowitz

    Background Vagus nerve stimulation is an investigational anti-inflammatory therapy targeting the nervous system to modulate immune activity. This study evaluated the efficacy and safety of transcutaneous auricular VNS (ta-VNS) in patients with pediatric-onset Crohn’s disease (CD) or ulcerative colitis (UC). Methods Participants were 10–21 years of age with mild/moderate CD or UC and fecal calprotectin (FC) > 200 ug/g within 4 weeks of study entry. Subjects were randomized to receive either ta-VNS targeting the cymba conchae of the external left ear, or sham stimulation for a 2-week duration followed by a cross over to the alternative stimulation for an additional 2 weeks. At week 4, all subjects received ta-VNS twice daily until week 16. Primary study endpoints were clinical remission, and a ≥ 50% reduction in FC level from baseline to week 16. Results Twenty-two subjects were enrolled (10 CD, 12 UC). Six of 10 with CD had a wPCDAI > 12.5 and 6/12 with UC had a PUCAI > 10 at baseline, correlating to mild to moderate symptom activity. Among the 12 subjects with active disease indices at baseline, clinical remission was achieved in 3/6 (50%) with CD and 2/6 (33%) with UC at week 16. Despite high FC levels within 4 weeks of enrollment, five subjects (4 UC, 1 CD) had FC levels < 200 at the baseline visit and were excluded from the FC analysis. Of the remaining 17, median baseline FC was 907 µg/g (IQR 411-2,120). At week 16, 11/17 (64.7%) of those with baseline FC ≥ 200 had a ≥ 50% reduction in FC (95% CI 38.3–85.8). In the UC subjects, there was an 81% median reduction in FC vs baseline (833 µg/g; p = 0.03) while in the CD subjects, median reduction in FC at 16 weeks was 51% (357 µg/g; p = 0.09). There were no safety concerns. Conclusion Noninvasive ta-VNS attenuated signs and symptoms in a pediatric cohort with mild to moderate inflammatory bowel disease Trial Registration NCT03863704 - Date of registration 3/4/2019


  • The Natural History of Crohn Disease in Children

    by Benjamin Sahn, James Markowitz

  • Open Access

    Coil‐Localized Laparoscopic‐Assisted Resection of Symptomatic Gastrointestinal Vascular Malformations in Children and Young Adults

    by Fikadu Worede, Thane A. Md Blinman, Tricia R. Bhatti, Petar Mamula, Benjamin Sahn, Abhay Srinivasan, Anne Marie Mbbch Cahill

    Background: Gastrointestinal (GI) bleeding from pediatric vascular malformation is uncommon and difficult to diagnose and manage. The preferred treatment is surgical resection; however, it can be challenging to precisely localize the lesion, particularly if it is not serosal.Objectives: To describe a technique of intentional preoperative coil localization of symptomatic pediatric GI vascular malformations by pediatric interventional radiology to facilitate fluoroscopically assisted laparoscopic resection.Methods: We searched the electronic privacy information center and picture archive and communication system in our center and found 3 cases. The electronic privacy information center and picture archive and communication system databases were the sources for retrieval of demographic, medical, radiological, and procedural information in all 3 cases.Results: After many nondiagnostic investigations in all 3 patients, a GI vascular malformation as a cause of GI bleeding was diagnosed with computed tomography angiography/magnetic resonance angiography and catheter angiography. A preoperative 0.018‐inch Hilal coil was placed as close as possible to the vascular malformation during super selective angiography. Laparoscopic surgery was performed within 24 hours of coil placement. In all cases, histology confirmed the resected bowel lesions to be vascular malformations.Conclusions: Intentional endovascular coil localization has the potential to increase the precision of lesion localization and may reduce laparoscopic operative time, when guided by the coil position.


  • Features of Intestinal Disease Associated With COVID‐Related Multisystem Inflammatory Syndrome in Children

    by Benjamin Sahn, Ogechukwu P. Eze, Morris C. Edelman, Christina E. Chougar, Rebecca M. Thomas, Charles L. Md Schleien, Toba Weinstein

    Multisystem inflammatory syndrome in children (MIS‐C) is a recently identified syndrome that appears to be temporally associated with novel coronavirus 2019 infection. MIS‐C presents with fever and evidence of systemic inflammation, which can manifest as cardiovascular, pulmonary, neurologic, and gastrointestinal (GI) system dysfunction. Presenting GI symptoms are seen in the majority, including abdominal pain, diarrhea, and vomiting. Any segment of the GI tract may be affected; however, inflammation in the ileum and colon predominates. Progressive bowel wall thickening can lead to luminal narrowing and obstruction. Most will have resolution of intestinal inflammation with medical therapies; however, in rare instances, surgical resection may be required.


  • Histological features of ileitis differentiating pediatric Crohn disease from ulcerative colitis with backwash ileitis

    by Benjamin Sahn, Vera De Matos, Ronen Stein, Eduardo Ruchelli, Samuel Masur, Andrew J. Klink, Robert N. Baldassano, David A. Piccoli, Pierre Russo, Petar Mamula